Suppr超能文献

AXL的药物抑制作用可抑制食管鳞状细胞癌的肿瘤生长和侵袭。

Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma.

作者信息

Han Sha, Wang Yequan, Ge Chengyan, Gao Mingtao, Wang Xintong, Wang Feiyu, Sun Lei, Li Sheng, Dong Tingting, Dang Zhen, Cui Wen, Zhang Guoan, Liu Ning

机构信息

Collaborative Innovation Center for Birth Defect Research and Transformation of Shandong Province, Jining Medical University, Jining, Shandong 272067, P.R. China.

Institute of Forensic Medicine and Laboratory Medicine, Forensic Science Center of Jining, Jining Medical University, Jining, Shandong 272067, P.R. China.

出版信息

Exp Ther Med. 2020 Nov;20(5):41. doi: 10.3892/etm.2020.9169. Epub 2020 Sep 2.

Abstract

Esophageal squamous cell carcinoma (ESCC) is a common type of cancer in a number of regions of the world, including East Asia, South Africa and Iran. It is often associated with poor prognosis rates. Tyrosine-protein kinase receptor UFO (AXL) is overexpressed in a subset of ESCC tumors, therefore the present study aimed to determine the effect of R428, a selective inhibitor of AXL, on ESCC tumor cells. TE1 and KYSE150 cell lines were used as models to investigate the effects of R428 treatment. The proliferative rate of the tumor cells was analyzed using MTT and colony formation assays. In addition, cell migration and invasion rates were analyzed using wound healing and Matrigel assays, respectively. The expression levels of matrix metalloproteinase (MMP)2 and MMP9, and the activation of protein kinase B (AKT), extracellular signal-regulated kinase (ERK) and AXL signaling were analyzed using gelatin zymography and western blotting. The results revealed that R428 inhibited the proliferative and invasive abilities of both cell lines. Furthermore, AXL, AKT and ERK signaling were all decreased in response to R428 treatment, alongside the expression levels of MMP2 and MMP9. In conclusion, the results of the present study suggested that R428 treatment may suppress ESCC tumor cell proliferation and invasion, representing a potential therapeutic target for ESCC.

摘要

食管鳞状细胞癌(ESCC)是世界上许多地区常见的癌症类型,包括东亚、南非和伊朗。它通常与较差的预后率相关。酪氨酸蛋白激酶受体UFO(AXL)在一部分ESCC肿瘤中过度表达,因此本研究旨在确定AXL的选择性抑制剂R428对ESCC肿瘤细胞的影响。使用TE1和KYSE150细胞系作为模型来研究R428处理的效果。使用MTT和集落形成试验分析肿瘤细胞的增殖率。此外,分别使用伤口愈合试验和基质胶试验分析细胞迁移和侵袭率。使用明胶酶谱法和蛋白质印迹法分析基质金属蛋白酶(MMP)2和MMP9的表达水平,以及蛋白激酶B(AKT)、细胞外信号调节激酶(ERK)和AXL信号通路的激活情况。结果显示,R428抑制了两种细胞系的增殖和侵袭能力。此外,响应R428处理,AXL、AKT和ERK信号通路均降低,同时MMP2和MMP9的表达水平也降低。总之,本研究结果表明,R428处理可能抑制ESCC肿瘤细胞的增殖和侵袭,是ESCC的一个潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed86/7480165/66383a32f78c/etm-20-05-09169-g00.jpg

相似文献

1
Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma.
Exp Ther Med. 2020 Nov;20(5):41. doi: 10.3892/etm.2020.9169. Epub 2020 Sep 2.
2
Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC).
Front Oncol. 2019 Nov 6;9:1138. doi: 10.3389/fonc.2019.01138. eCollection 2019.
3
Epb41l3 suppresses esophageal squamous cell carcinoma invasion and inhibits MMP2 and MMP9 expression.
Cell Biochem Funct. 2016 Apr;34(3):133-41. doi: 10.1002/cbf.3170. Epub 2016 Feb 24.
9
BRCA1-Associated Protein Increases Invasiveness of Esophageal Squamous Cell Carcinoma.
Gastroenterology. 2017 Nov;153(5):1304-1319.e5. doi: 10.1053/j.gastro.2017.07.042. Epub 2017 Aug 2.
10
[Effects of microRNA-182-5p on cell proliferation and invasion of esophageal squamous cell carcinoma and related molecular mechanisms].
Zhonghua Zhong Liu Za Zhi. 2020 Aug 23;42(8):635-643. doi: 10.3760/cma.j.cn112152-20200310-00191.

引用本文的文献

1
A Bioinformatic Assay of Quercetin in Gastric Cancer.
Int J Mol Sci. 2024 Jul 20;25(14):7934. doi: 10.3390/ijms25147934.
2
AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers.
Mol Clin Oncol. 2023 Feb 8;18(3):22. doi: 10.3892/mco.2023.2618. eCollection 2023 Mar.
3
KISS-1, Mediated by Promoter Methylation, Suppresses Esophageal Squamous Cell Carcinoma Metastasis via MMP2/9/MAPK Axis.
Dig Dis Sci. 2022 Oct;67(10):4780-4796. doi: 10.1007/s10620-021-07335-1. Epub 2022 Jan 7.

本文引用的文献

1
Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC).
Front Oncol. 2019 Nov 6;9:1138. doi: 10.3389/fonc.2019.01138. eCollection 2019.
2
Engineered AXL-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration.
Oncol Lett. 2019 Jun;17(6):5784-5792. doi: 10.3892/ol.2019.10255. Epub 2019 Apr 15.
3
Function of Axl receptor tyrosine kinase in non-small cell lung cancer.
Oncol Lett. 2018 Mar;15(3):2726-2734. doi: 10.3892/ol.2017.7694. Epub 2017 Dec 27.
4
AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
Oncol Lett. 2018 Feb;15(2):1900-1906. doi: 10.3892/ol.2017.7443. Epub 2017 Nov 20.
6
AXL-Driven EMT State as a Targetable Conduit in Cancer.
Cancer Res. 2017 Jul 15;77(14):3725-3732. doi: 10.1158/0008-5472.CAN-17-0392. Epub 2017 Jun 30.
7
Molecular insights of Gas6/TAM in cancer development and therapy.
Cell Death Dis. 2017 Mar 23;8(3):e2700. doi: 10.1038/cddis.2017.113.
8
Role of AXL expression in non-small cell lung cancer.
Oncol Lett. 2016 Dec;12(6):5085-5091. doi: 10.3892/ol.2016.5356. Epub 2016 Nov 7.
10
Cancer statistics in China, 2015.
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验